

**FOR IMMEDIATE RELEASE**

## **Cogmedix to Manufacture First FDA Cleared ADHD Detection Device**

*BioBehavioral Diagnostics Company joins a growing list of leading medical device companies choosing Cogmedix as its domestic contract manufacturer*

**WORCESTER, Mass. – May 28, 2009 – [Cogmedix](#)**, a US-based, FDA compliant contract manufacturer for medical and clinical devices, today announced its selection as the contract manufacturer of the first FDA cleared Attention Deficit Hyperactivity Disorder (ADHD) testing device. [BioBehavioral Diagnostics Company](#), a leading developer of diagnostic systems that aid clinicians in the objective assessment of behavioral and neurobiological disorders, selected Cogmedix to deliver a reliable and compliant manufacturing outsourcing option for its Quotient™ ADHD System. BioBehavioral Diagnostics joins a growing list of medical device companies working with Cogmedix to manufacture devices in the US rather than acquiring manufacturing services overseas.

BioBehavioral Diagnostics' Quotient ADHD System provides healthcare professionals with an office-based device to rapidly and precisely measure the symptom load of the three core symptoms of ADHD (inattention, hyperactivity and impulsivity). The behavioral assessment is immediately presented to a clinician through a secure web based portal in a Quotient Patient Report. This report provides objective measures of behavioral disorder severity against which subsequent assessments can be made to aid the clinician in medication selection, titration and management decisions.

“Cogmedix’s extensive experience manufacturing devices for medical development companies like ours made it the clear partner choice to build the Quotient ADHD System,” said Eric Gordon, Founder and member of the Board of Directors, BioBehavioral Diagnostics. “We take a great deal of pride in our technology, and require a partner who demonstrates the same sense of pride in their work. Cogmedix’s commitment to deliver the highest quality manufacturing solutions and customer service makes it an ideal long-term partner for our business.”

“Given the increased attention to behavioral disorders, and the difficulty in assessing and treating them, it is clear clinicians need systems to help them make accurate diagnoses,” said Chris Coghlin, Founder and CEO, Cogmedix. “We’re proud to assist BioBehavioral Diagnostics in this effort with our cost-effective, domestic manufacturing capabilities, which put us in a strong position to satisfy the company’s needs as it continues to grow.”

### **About BioBehavioral Diagnostics Company**

BioBehavioral Diagnostics Company (BioBDx) is a privately held company whose mission is to develop, manufacture, and market proprietary systems for the quantitative assessment of behavioral disorders. BioBDx develops diagnostic systems that aid clinicians in the objective

assessment of behavioral and neurobiological disorders, and is leading the way towards a transformation of behavioral and neurobiological medicine, in which the diagnosis and treatment of difficult-to-establish neurological and psychiatric conditions can be made rapidly, objectively, and quantifiably. The company's lead product, the Quotient™ ADHD System, is designed to enable physicians to accurately make office-based diagnoses for ADHD, ensuring prompt and appropriate treatment. For more information about BioBDx, please visit [www.biobdx.com](http://www.biobdx.com).

### **About Cogmedix**

Cogmedix is a US-based, FDA compliant contract manufacturer for medical and clinical devices. A subsidiary of Coghlin Companies Inc., Cogmedix focuses on the production of Class I and Class II medical and clinical devices for the critical care, home healthcare, emergency room, and industrial laboratories markets. Cogmedix focuses on aligning itself with companies seeking a compliant, conscientious, cost effective, domestic manufacturing resource to assist them with volume turnkey manufacturing. For more information about Cogmedix, please visit [www.cogmedix.com](http://www.cogmedix.com).

###

Media Contact:

Dawn Sullivan or Katie Delach

Hart-Boillot

781-893-0053

[Coghlin@hartboillot.com](mailto:Coghlin@hartboillot.com)